ライフサイエンスコーパス: anaplastic lymphoma kinase

1 portion of the receptor tyrosine kinase ALK (anaplastic lymphoma kinase).

2 es the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphoma kinase).

3 molecular target for the kinase activity of anaplastic lymphoma kinase.

4 expression was not related to expression of anaplastic lymphoma kinase-1.

5 The proto-oncogene ALK encodes anaplastic lymphoma kinase, a receptor tyrosine kinase t

6 he presence of a translocation involving the anaplastic lymphoma kinase ALK gene.

7 ide 1 was identified as a novel inhibitor of anaplastic lymphoma kinase (ALK enzyme assay IC(50) = 0.

8 Anaplastic lymphoma kinase (ALK) -positive anaplastic la

9 Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4

10 The tyrosine kinase receptor anaplastic lymphoma kinase (ALK) and its ligand, the gro

11 Anaplastic lymphoma kinase (Alk) and leucocyte tyrosine

12 Activation of Anaplastic lymphoma kinase (ALK) and leukocyte tyrosine

13 belly (Jeb) and its receptor tyrosine kinase Anaplastic lymphoma kinase (Alk) are localized to develo

14 ncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgro

15 We discovered anaplastic lymphoma kinase (ALK) as a candidate thinness

16 We have recently identified anaplastic lymphoma kinase (ALK) as a tyrosine kinase re

17 recently identified nucleophosmin (NPM) and anaplastic lymphoma kinase (ALK) as the genes on chromos

18 t inhibitors of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) blocked D2R desensitiza

19 The phylogenetic proximity of the ROS1 and anaplastic lymphoma kinase (ALK) catalytic domains led t

20 Abnormal expression of constitutively active anaplastic lymphoma kinase (ALK) chimeric proteins in th

21 essed CD30, epithelial membrane antigen, and anaplastic lymphoma kinase (ALK) consistent with a null

22 Anaplastic lymphoma kinase (ALK) constitutes a part of t

23 epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) define two unique subty

24 We demonstrate that anaplastic lymphoma kinase (Alk) efficiently protects ne

25 lymphoma (ALCL) is a T-cell lymphoma, whose anaplastic lymphoma kinase (ALK) expression varies accor

26 distinguished by the presence or absence of anaplastic lymphoma kinase (ALK) expression.

27 This review describes the identification of anaplastic lymphoma kinase (ALK) fusion genes in approxi

28 microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represe

29 ag in this study and was used to degrade the anaplastic lymphoma kinase (ALK) fusion protein by linki

30 microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion protein, presume

31 Oncogenic anaplastic lymphoma kinase (ALK) fusion proteins (nucleo

32 Anaplastic lymphoma kinase (ALK) fusion variants in Non-

33 Rearrangements involving the anaplastic lymphoma kinase (ALK) gene are defining event

34 d here to detection of rearrangements in the anaplastic lymphoma kinase (ALK) gene associated with AL

35 ssed nucleophosmin (NPM) gene at 5q35 to the anaplastic lymphoma kinase (ALK) gene at 2p23, which is

36 Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hered

37 The anaplastic lymphoma kinase (ALK) gene fuses to the nucle

38 he discovery of rearrangements involving the anaplastic lymphoma kinase (ALK) gene in thyroid cancer.

39 The Anaplastic Lymphoma Kinase (ALK) gene is a receptor tyro

40 The anaplastic lymphoma kinase (ALK) gene is characteristica

41 as (ALCLs) carry translocations in which the anaplastic lymphoma kinase (ALK) gene is juxtaposed to v

42 normalities of 2p23 and rearrangement of the anaplastic lymphoma kinase (ALK) gene locus.

43 Molecular testing is positive for an anaplastic lymphoma kinase (ALK) gene rearrangement usin

44 Anaplastic lymphoma kinase (ALK) gene rearrangements are

45 In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are

46 dermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene rearrangements.

47 Patients positive for the anaplastic lymphoma kinase (ALK) gene showed elevated sI

48 (2;5)(p23;q35) translocation which fuses the Anaplastic Lymphoma Kinase (ALK) gene with the Nucleopho

49 uently carry oncogenic fusions involving the anaplastic lymphoma kinase (ALK) gene.

50 Aberrant activation of anaplastic lymphoma kinase (ALK) has been described in a

51 Anaplastic lymphoma kinase (Alk) has been proposed to re

52 Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in

53 Activating point mutations in Anaplastic Lymphoma Kinase (ALK) have positioned ALK as

54 2 gene, which, we show, encodes the nematode anaplastic lymphoma kinase (ALK) homolog, a proto-oncoge

55 usly shown both humoral and CTL responses to anaplastic lymphoma kinase (ALK) in patients with ALK-po

56 Analogues structurally related to anaplastic lymphoma kinase (ALK) inhibitor 1 were optimi

57 Here we investigated anaplastic lymphoma kinase (ALK) inhibitor resistance in

58 Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, which has sh

59 Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type

60 find that anaplastic lymphoma kinase (ALK) inhibitors can enhance

61 that may rationalize clinical evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this sett

62 lending impetus to the development of novel anaplastic lymphoma kinase (ALK) inhibitors with differe

63 naene macrocycles were prepared as potential anaplastic lymphoma kinase (ALK) inhibitors, designed to

64 Anaplastic lymphoma kinase (ALK) is a promising new targ

65 Targeting Anaplastic lymphoma kinase (ALK) is a promising therapeu

66 Anaplastic lymphoma kinase (ALK) is a promising therapeu

67 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

68 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

69 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

70 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

71 Anaplastic lymphoma kinase (Alk) is a receptor tyrosine

72 The anaplastic lymphoma kinase (ALK) is a receptor tyrosine

73 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

74 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

75 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

76 Anaplastic lymphoma kinase (ALK) is a transmembrane rece

77 Here we show that the anaplastic lymphoma kinase (ALK) is aberrantly activated

78 The anaplastic lymphoma kinase (ALK) is chromosomally rearra

79 The orphan receptor anaplastic lymphoma kinase (ALK) is one of very few RTKs

80 Here we show that transcription of anaplastic lymphoma kinase (Alk) is repressed by LMO4 in

81 MYCN overexpression combined with activated anaplastic lymphoma kinase (ALK) is sufficient to induce

82 Genetic rearrangements of the anaplastic lymphoma kinase (ALK) kinase occur in 3% to 1

83 ely half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p2

84 Activating anaplastic lymphoma kinase (ALK) mutations are frequentl

85 Anaplastic lymphoma kinase (ALK) mutations occur in 3% t

86 malignant transformation of T cells that are anaplastic lymphoma kinase (ALK) negative and CD30 posit

87 The anaplastic lymphoma kinase (ALK) on 2p23 is a tyrosine k

88 microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) oncogenic fusion protei

89 Anaplastic lymphoma kinase (ALK) oncogenic fusions are a

90 The metabolic shift is mediated through the anaplastic lymphoma kinase (ALK) phosphorylation of the

91 , we found that a selective inhibitor of the anaplastic lymphoma kinase (ALK) potently suppressed gro

92 developed a folate-caged pomalidomide-based anaplastic lymphoma kinase (ALK) PROTAC, FA-S2-MS4048, w

93 The aim of this study is to investigate anaplastic lymphoma kinase (ALK) protein expression and

94 hromosomal translocations that juxtapose the anaplastic lymphoma kinase (ALK) proto-oncogene to a dim

95 growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements have dem

96 The anaplastic lymphoma kinase (ALK) receptor is expressed b

97 l fusion gene that incorporates parts of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinas

98 Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinas

99 ent work identified ALKAL2, a ligand for the Anaplastic Lymphoma Kinase (ALK) receptor, as a key medi

100 the oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) remain only partially u

101 romoting phenotype through activation of the anaplastic lymphoma kinase (ALK) signaling pathway.

102 Here we report a novel isoform of the anaplastic lymphoma kinase (ALK) that is expressed in ap

103 and rhabdomyosarcoma, harbour activation of anaplastic lymphoma kinase (ALK) through different mecha

104 aim of the present review is to describe the anaplastic lymphoma kinase (ALK) translocation as a prom

105 sets of lung cancers with EGFR mutations and anaplastic lymphoma kinase (ALK) translocations.

106 ormation mediated by the nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) tyrosine kinase are onl

107 Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

108 a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

109 h epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

110 epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

111 epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

112 Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

113 ell transformation mediated by the oncogenic anaplastic lymphoma kinase (ALK) tyrosine kinase remain

114 n protein containing the catalytic domain of anaplastic lymphoma kinase (ALK) under the control of th

115 Anaplastic Lymphoma Kinase (ALK) was originally identifi

116 protein (p80) derived from the fusion of the anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM

117 ;5)(p23;q35) results in the juxtaposition of anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM

118 t down-regulation of TIMP1 expression in two anaplastic lymphoma kinase (ALK)(+) ALCL cell lines, Kar

119 vered in many T-cell malignancies, including anaplastic lymphoma kinase (ALK)(-) anaplastic large cel

120 Anaplastic lymphoma kinase (ALK)(1) and the related leuk

121 Genetic studies have established anaplastic lymphoma kinase (ALK), a cell surface recepto

122 ntained chromosomal translocations involving anaplastic lymphoma kinase (ALK), a novel receptor tyros

123 Jeb receptor is the Drosophila homologue of anaplastic lymphoma kinase (Alk), a receptor tyrosine ki

124 Anaplastic lymphoma kinase (ALK), a receptor tyrosine ki

125 a distinct role for one of the DMGs encoding anaplastic lymphoma kinase (ALK), an important regulator

126 se domain that is physiologically related to anaplastic lymphoma kinase (ALK), and is undergoing Phas

127 EGFR), rearranged during transfection (RET), anaplastic lymphoma kinase (ALK), and MAPK1/3 and other

128 ts in nonsmall cell lung cancer fuse EML4 to anaplastic lymphoma kinase (ALK), causing expression of

129 Anaplastic lymphoma kinase (ALK), EGF receptor (EGFR), a

130 otubule-associated protein like 4 (EML4) and anaplastic lymphoma kinase (ALK), generated by an invers

131 Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), has also recently show

132 ecently identified receptor tyrosine kinase, anaplastic lymphoma kinase (ALK), in embryonic chick by

133 of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), KRAS, and BRAF, induce

134 by R1-R6 axons interacts with its receptor, anaplastic lymphoma kinase (Alk), on budding dendrites t

135 omosome 5q35 to a novel protein kinase gene, Anaplastic Lymphoma Kinase (ALK), on chromosome 2p23.

136 Anaplastic lymphoma kinase (ALK), physiologically expres

137 Anaplastic lymphoma kinase (ALK), physiologically expres

138 e phosphatase receptor zeta (PTPRZ1) and the anaplastic lymphoma kinase (ALK), respectively.

139 genes encoding the receptor tyrosine kinases anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (

140 r (TKI) with specificity for gene rearranged anaplastic lymphoma kinase (ALK), such as the EML4-ALK,

141 MK binds to anaplastic lymphoma kinase (ALK), the receptor for PTN,

142 lating evidence indicates that expression of anaplastic lymphoma kinase (ALK), typically due to t(2;5

143 ), human epidermal growth factor receptor 2, anaplastic lymphoma kinase (ALK), v-Raf murine sarcoma v

144 A gene residing in this locus, the anaplastic lymphoma kinase (Alk), was expressed at signi

145 MYCN and Anaplastic Lymphoma Kinase (ALK), which are often involv

146 SCD-2, the C. elegans ortholog of mammalian anaplastic lymphoma kinase (ALK), which has been implica

147 YCN cooperates with mutational activation of anaplastic lymphoma kinase (ALK), which promotes progres

148 absence of translocations that activate the anaplastic lymphoma kinase (ALK), with nucleophosmin-ALK

149 For comparison, CNAs for anaplastic lymphoma kinase (ALK)- nodal anaplastic large

150 ied, angioimmunoblastic T-cell lymphoma, and anaplastic lymphoma kinase (ALK)-negative anaplastic lar

151 Anaplastic lymphoma kinase (ALK)-negative anaplastic lar

152 d) and active (underphosphorylated), in four anaplastic lymphoma kinase (ALK)-positive ALCL cell line

153 Anaplastic lymphoma kinase (ALK)-positive anaplastic lar

154 e SHH/GLI1 signaling pathway is activated in anaplastic lymphoma kinase (ALK)-positive anaplastic lar

155 Anaplastic lymphoma kinase (ALK)-positive anaplastic lar

156 ssion was seen in only 1 of 15 patients with anaplastic lymphoma kinase (ALK)-positive anaplastic lar

157 orrelates with relapse risk in children with anaplastic lymphoma kinase (ALK)-positive anaplastic lar

158 a small subset of cells purified from human anaplastic lymphoma kinase (ALK)-positive and -negative,

159 ngioimmunoblastic T-cell lymphoma (AITL), 31 anaplastic lymphoma kinase (ALK)-positive and 48 ALK-neg

160 heterogeneous disease that includes systemic anaplastic lymphoma kinase (ALK)-positive and ALK-negati

161 While most anaplastic lymphoma kinase (ALK)-positive non-Hodgkin ly

162 h crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell

163 positive T-cell lymphoma, comprises systemic anaplastic lymphoma kinase (ALK)-positive, and ALK-negat

164 ere, we perform a phosphoproteomic screen in anaplastic lymphoma kinase (ALK)-rearranged ("ALK+") pat

165 oma, small molecule inhibitor crizotinib for anaplastic lymphoma kinase (ALK)-rearranged inflammatory

166 In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer,

167 cacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-ce

168 Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto

169 Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK

170 scaffold will be described for inhibitors of anaplastic lymphoma kinase (ALK).

171 somatic aberrations in the gene encoding for anaplastic lymphoma kinase (ALK).

172 he dimerization domain of nucleophosmin with anaplastic lymphoma kinase (ALK).

173 express the receptor for this growth factor, anaplastic lymphoma kinase (ALK).

174 (ECD) of the orphan receptor tyrosine kinase anaplastic lymphoma kinase (ALK).

175 smic portion of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).

176 2;5)(p23;q35) resulting in overexpression of anaplastic lymphoma kinase (ALK).

177 smic portion of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).

178 pression of CD30 and a lack of expression of anaplastic lymphoma kinase (ALK).

179 eloped as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).

180 lymphomas characterized by the expression of anaplastic lymphoma kinase (ALK+ TCL) fail to express th

181 leophosmin/B23 (NPM) gene (5q35) and a novel anaplastic lymphoma kinase (ALK; 2p23) are the fused gen

182 chimeric tyrosine kinase nucleophosmin (NPM)-anaplastic lymphoma kinase [ALK; ALK(+) T-cell lymphoma

183 h epidermal growth factor receptor [EGFR] or anaplastic lymphoma kinase [ALK] genetic alterations wer

184 or survivin expression in 62 ALCL tumors (30 anaplastic lymphoma kinase [ALK]-positive and 32 ALK-neg

185 r inhibitors, 2.46% (range, 1.75%-4.66%) for anaplastic lymphoma kinase and ROS1 inhibitors, and 3.06

186 to be independent of nuclear localization of anaplastic lymphoma kinase; and phospholipase C-gamma wa

187 2;5) were mapped; constitutive activation of anaplastic lymphoma kinase by a chromosomal inversion wa

188 During the last year the expression of anaplastic lymphoma kinase clarified presentation and pr

189 PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >12

190 noderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion protein is

191 noderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion protein.

192 idermal growth factor receptor mutations and anaplastic lymphoma kinase fusions, but significantly re

193 timal first-line treatment for patients with anaplastic lymphoma kinase fusions.

194 p studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associat

195 xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are de

196 ells that are sensitive and resistant to the anaplastic lymphoma kinase inhibitor alectinib.

197 r inhibitors, 0.999 (range, 0.982-0.999) for anaplastic lymphoma kinase inhibitors, and 0.999 for BRA

198 epidermal growth factor receptor inhibitors, anaplastic lymphoma kinase inhibitors, ROS1 inhibitors,

199 , we determined that the Midkine-a receptor, anaplastic lymphoma kinase, is upstream of the HLH regul

200 cell lymphoma (BIA-ALCL) is a CD30-positive, anaplastic lymphoma kinase-negative T-cell lymphoma.

201 CD30(+) T cell lymphoproliferative disorder (anaplastic lymphoma kinase-negative) 3 years after recei

202 d the resulting fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) are detected in 50%

203 utively active tyrosine kinase nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) expressing anaplast

204 Constitutive overexpression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a key oncogenic

205 Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is an aberrant fusi

206 ction of the nucleolar protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) protein.

207 mation of the chimeric protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), which possesses si

208 ting in aberrant expression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

209 neration of the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

210 ;q35) and aberrantly expresses nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

211 oncogenic fusion protein: the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

212 neration of the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).

213 The nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)/phospholipase C-gam

214 ted by the oncogenic, chimeric nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) tyrosine kinase rem

215 plying these design principles, we developed anaplastic lymphoma kinase oncoprotein-targeting PROTACs

216 microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cel

217 t this receptor is expressed on T cells from anaplastic lymphoma kinase-positive (ALK(+)) anaplastic

218 r angioimmunoblastic T-cell lymphoma (AITL), anaplastic lymphoma kinase-positive (ALK(+)) anaplastic

219 Using conditional transgenic models of anaplastic lymphoma kinase-positive (ALK(+)) lymphomas a

220 Anaplastic lymphoma kinase-positive (ALK+) ALCL is assoc

221 In anaplastic lymphoma kinase-positive (ALK+) ALCL, WASP an

222 Anaplastic lymphoma kinase-positive (ALK-positive) disea

223 Using nucleophosmin-anaplastic lymphoma kinase-positive (NPM-ALK(+)) anaplas

224 sociated T-cell lymphoma patients (excluding anaplastic lymphoma kinase-positive anaplastic large cel

225 Anaplastic lymphoma kinase-positive anaplastic large-cel

226 d in a caspase-dependent manner in apoptotic anaplastic lymphoma kinase-positive, anaplastic large ce

227 For patients with an anaplastic lymphoma kinase rearrangement, a performance

228 For patients with an anaplastic lymphoma kinase rearrangement, a PS of 0-2, a

229 accompanied by mutational activation of ALK (anaplastic lymphoma kinase), suggesting their pathogenic

230 clude the possibility of an EGFR mutation or anaplastic lymphoma kinase translocation or to identify

231 assively parallel sequencing instrument, and anaplastic lymphoma kinase translocation was evaluated b

232 vity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors ha